Boston Scientific

The Worldwide Kidney Stone Retrieval Devices Industry is Expected to Reach $3.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.

Key Points: 
  • Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.
  • Considerably smaller ureter scopes, quartz fibers, and lithotripter probes have made the extraction of kidney stones from previously unreachable locations far safer than traditional surgical options.
  • For instance, the Dretler stone cone is one innovation that inhibits stone migration during the treatment.
  • The demand for kidney stone retrieval devices was uneven, with installation delays and a decline in manufacturing during the pandemic.

MicroTransponder Completes $73M Series E Financing

Retrieved on: 
Wednesday, September 21, 2022

AUSTIN, Texas, Sept. 21, 2022 /PRNewswire/ -- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO). The funding supports the market development and commercialization of MicroTransponder's FDA-approved Vivistim® Paired VNS™ System, a first-of-its-kind breakthrough technology that uses vagus nerve stimulation (VNS) during rehabilitation therapy to improve upper limb function for stroke survivors.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2022 /PRNewswire/ -- MicroTransponder, Inc. positions for continued strategic growth, having finalized its oversubscribed $73 million Series E funding round and named Prashant Rawat chief operating officer (COO).
  • The company's Series E was led by US Venture Partners , a multi-stage investment firm.
  • For more information about MicroTransponder and the first FDA-approved use of vagus nerve stimulation for stroke rehabilitation, visit Vivistim.com.
  • MicroTransponder, Inc. is a privately held, global medical device company based in Austin, Texas, committed to developing research-based neuroscience solutions.

Global Urinary Incontinence (MedCore) Market Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The "Urinary Incontinence Market Report with COVID Impact - Global - 2022 - 2028 - MedCore" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Urinary Incontinence Market Report with COVID Impact - Global - 2022 - 2028 - MedCore" report has been added to ResearchAndMarkets.com's offering.
  • The complete report suite on the global market for urinary incontinence device market includes urethral bulking agents (UBAs) and incontinence slings.
  • The urinary incontinence sling market is segmented into female and male urinary incontinence slings.
  • Global Urinary Incontinence Sling Market - Further segmented into:
    Female and male urinary incontinence slings.

ViVitro Labs Introduces World's first "Set it and forget it" Heart Valve Durability Tester

Retrieved on: 
Friday, September 16, 2022

VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ - ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related consulting services, announces the launch of a revolutionary, self-regulating heart valve durability tester, the ViVitro Labs Heart Valve Durability Tester with ADC technology ( https://vivitrolabs.com/product/adc-heart-valve-durability-tester/ ) at TCT 2022 in booth 542 on September 17-19, 2022, at the Boston Convention and Exhibition Center (BCEC)".

Key Points: 
  • VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ - ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related consulting services, announces the launch of a revolutionary, self-regulating heart valve durability tester, the ViVitro Labs Heart Valve Durability Tester with ADC technology ( https://vivitrolabs.com/product/adc-heart-valve-durability-tester/ ) at TCT 2022 in booth 542 on September 17-19, 2022, at the Boston Convention and Exhibition Center (BCEC)".
  • Heart Valve Durability Testers measure the longevity and performance of artificial heart valve prostheses in accelerated conditions to ensure devices are safe before being used in patients.
  • The team incorporated feedback from industry leading cardiovascular device companies, start-ups, universities, testing labs, and consultants throughout the process.
  • The ViVitro Labs Heart Valve Durability Tester received enthusiastic praise during preliminary product evaluation demonstrations over the past 10 months from companies including Medtronic, Edwards, Abbott, and Boston Scientific.

ViVitro Labs Introduces World's first "Set it and forget it" Heart Valve Durability Tester

Retrieved on: 
Friday, September 16, 2022

VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ -- ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related consulting services, announces the launch of a revolutionary, self-regulating heart valve durability tester, the ViVitro Labs Heart Valve Durability Tester with ADC™ technology (https://vivitrolabs.com/product/adc-heart-valve-durability-tester/ ) at TCT 2022 in booth 542 on September 17-19, 2022, at the Boston Convention and Exhibition Center (BCEC)".

Key Points: 
  • VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ -- ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related consulting services, announces the launch of a revolutionary, self-regulating heart valve durability tester, the ViVitro Labs Heart Valve Durability Tester with ADC technology ( https://vivitrolabs.com/product/adc-heart-valve-durability-tester/ ) at TCT 2022 in booth 542 on September 17-19, 2022, at the Boston Convention and Exhibition Center (BCEC)".
  • Heart Valve Durability Testers measure the longevity and performance of artificial heart valve prostheses in accelerated conditions to ensure devices are safe before being used in patients.
  • The team incorporated feedback from industry leading cardiovascular device companies, start-ups, universities, testing labs, and consultants throughout the process.
  • The ViVitro Labs Heart Valve Durability Tester received enthusiastic praise during preliminary product evaluation demonstrations over the past 10 months from companies including Medtronic, Edwards, Abbott, and Boston Scientific.

Nordson Corporation Appoints Milton Morris to Board of Directors

Retrieved on: 
Thursday, September 15, 2022

Nordson Corporation (NASDAQ: NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors.

Key Points: 
  • Nordson Corporation (NASDAQ: NDSN) announced the appointment of Dr. Milton Morris, recently retired president and chief executive officer of Neuspera Medical, Inc., to its board of directors.
  • Dr. Morris will bring robust business leadership experience, as well as a legacy of successful product innovation, to the board.
  • We look forward to bringing Miltons perspective to the board, said Michael Merriman, chair of the board of directors, Nordson Corporation.
  • I look forward to partnering with the Nordson board of directors and executive management team.

Global Remote Patient Monitoring (RPM) Devices and Equipment Market Report 2022: A $2.09 Billion Market in 2026 - Device Manufacturers are Increasingly Integrating IoT and Wireless Technology

Retrieved on: 
Thursday, September 15, 2022

Remote patient monitoring device manufacturers are increasingly integrating IoT and wireless technology with remote patient monitoring devices to efficiently diagnose and treat medical conditions.

Key Points: 
  • Remote patient monitoring device manufacturers are increasingly integrating IoT and wireless technology with remote patient monitoring devices to efficiently diagnose and treat medical conditions.
  • Global Remote Patient Monitoring Devices And Equipment Market, Segmentation By Type Of Device, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.2.
  • Global Remote Patient Monitoring Devices And Equipment Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
    6.3.
  • Global Remote Patient Monitoring Devices And Equipment Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022

AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

Key Points: 
  • AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
  • AVS is the first company to develop pulsatile intravascular lithotripsy, a therapy that is delivered through a balloon-based platform called PULSE.
  • We are excited by this first-in-human trial milestone we have achieved, added Mark Toland, President and Chief Executive Officer of AVS.
  • Kucheman added, I am delighted to join the AVS board and look forward to helping patients with limited treatment options.

Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Retrieved on: 
Thursday, September 15, 2022

At the same time, we are excited that he is leaving our commercial organization in such good hands.

Key Points: 
  • At the same time, we are excited that he is leaving our commercial organization in such good hands.
  • Ms. Goodman brings over 17 years of medical device sales experience, most recently serving as Profounds VP, U.S.
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.

Global Endoscopy Market Report 2022: Emergence of Capsule Endoscopy Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 15, 2022

The global endoscopy market is predicted to reach US$48.45 billion in 2026, growing at a CAGR of 7.50%, for the duration spanning 2022-2026.

Key Points: 
  • The global endoscopy market is predicted to reach US$48.45 billion in 2026, growing at a CAGR of 7.50%, for the duration spanning 2022-2026.
  • In terms of product, the global endoscopy market can be categorized into endoscopes, visualization systems, endoscopic ultrasound, insufflator and other.
  • According to application, the endoscopy market can be segmented into gastrointestinal endoscopy, laparoscopy, urology endoscopy, arthroscopy and others.
  • The report provides a comprehensive analysis of the global endoscopy market segmented on the basis of product, application, end-user and region.